Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.12.073 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.12.073 33385581!7771302!33385581     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 104 (ä): 433-440 Nephropedia Template TP {{tp|p=33385581|t=2021. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study |pdf=|usr=}}{{33385581}} gab.com Text Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33385581 #FOAvip OBJECTIVES: Canakinumab is an IL-1beta antibody that neutralises the activity of IL-1beta. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study: 33 patients (cases) signed informed consent and received canakinumab (Cohort 1) and 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (Cohort 2). RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs. 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared with Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO(2):FiO(2) (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side-effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI 43.6-89.1) for Cohort 2. CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care. Twit Text FOAVip Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33385581 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33385581 #FOAvip English Wikipedia <ref>{{Cite pmid|33385581}}</ref> Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study #MMPMID33385581 Generali D; Bosio G; Malberti F; Cuzzoli A; Testa S; Romanini L; Fioravanti A; Morandini A; Pianta L; Giannotti G; Viola EM; Giorgi-Pierfranceschi M; Foramitti M; Tira RA; Zangrandi I; Chiodelli G; Machiavelli A; Cappelletti MR; Giossi A; De Giuli V; Costanzi C; Campana C; Bernocchi O; Sirico M; Zoncada A; Molteni A; Venturini S; Giudici F; Scaltriti M; Pan A Int J Infect Dis 2021[Mar]; 104 (ä): 433-440 PMID33385581show ga OBJECTIVES: Canakinumab is an IL-1beta antibody that neutralises the activity of IL-1beta. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study: 33 patients (cases) signed informed consent and received canakinumab (Cohort 1) and 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (Cohort 2). RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs. 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared with Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO(2):FiO(2) (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side-effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI 43.6-89.1) for Cohort 2. CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |COVID-19/*complications[MESH] |Case-Control Studies[MESH] |Cohort Studies[MESH] |Female[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pneumonia, Viral/*complications/*drug therapy[MESH] |Prospective Studies[MESH] |SARS-CoV-2/immunology[MESH]Canakinumab as treatment for COVID-19-related pneumonia: A prospective(epmc).pdf DeepDyve Pubget Overpricing